Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong revenue growth and promising product development (TULSA AI and CAPTAIN trial) are offset by increased net losses and operating expenses. The Q&A section reveals positive feedback on CAPTAIN data and insurer engagement, but management's vague responses on deal closures and financial guidance introduce uncertainty. The lack of shareholder return initiatives further tempers optimism. Despite potential for future growth, current financial instability and competitive pressures suggest a neutral stock price movement in the short term.
Key Financial Performance
Revenue $2.6 million, increased 82% from $1.4 million in Q1 2024.
Gross Margin 71%, compared to 60% in Q1 2024.
Total Operating Expenses $13 million, compared with $8.7 million in Q1 2024.
Net Loss $10.7 million or $0.36 per common share, compared to a net loss of $6.6 million or $0.27 per common share in Q1 2024.
Cash Position $46.4 million as of March 31, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
TULSA AI volume reduction module: A new module leveraging AI for BPH treatment, with a limited release planned for June and full release in Q4 2025.
TULSA+ program: A turnkey solution for urologists to adopt TULSA technology, enhancing market penetration and patient access.
Revenue growth: First quarter 2025 revenue increased 82% to $2.6 million compared to Q1 2024.
Gross margin improvement: Gross margin in Q1 2025 was 71%, up from 60% in Q1 2024.
CAPTAIN trial results: Initial data from the CAPTAIN trial shows TULSA's superiority over robotic prostatectomy, enhancing market positioning.
Reimbursement strategy: Level 7 reimbursement for TULSA procedures effective January 1, 2025, broadening treatment settings and financial viability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-Looking Statements: The company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those implied.
Financial Performance Risks: The company reported a net loss of $10.7 million in Q1 2025, which is an increase from a net loss of $6.6 million in Q1 2024, indicating potential financial instability.
Regulatory Issues: The company is subject to regulatory scrutiny, particularly regarding the efficacy and safety of its technologies in treating various medical conditions.
Competitive Pressures: The introduction of competing technologies, such as robotic prostatectomy and focal ablation, poses a risk to TULSA's market share and adoption.
Supply Chain Challenges: The company may face challenges in the supply chain, particularly in acquiring necessary equipment and materials for the TULSA+ program.
Economic Factors: The financial viability of the TULSA+ program is contingent on assumptions regarding reimbursement rates and patient volume, which may be affected by broader economic conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
TULSA AI Volume Reduction Module: A new module leveraging AI for BPH treatment, expected to reduce procedure time to 60-90 minutes. Limited release planned for June 2025, full release in Q4 2025.
CAPTAIN Clinical Trial: Initial data from the CAPTAIN trial shows TULSA's superiority in safety and efficacy compared to robotic prostatectomy, with significant patient benefits.
TULSA+ Program: A turnkey solution for urologists to adopt TULSA technology, enhancing accessibility and financial viability for practices.
Reimbursement Codes: New Level 7 reimbursement codes effective January 1, 2025, applicable across various treatment settings, enhancing economic proposition.
Revenue Expectations: First quarter 2025 revenue of $2.6 million, an 82% increase from Q1 2024.
Gross Margin: Gross margin improved to 71% in Q1 2025 from 60% in Q1 2024.
Net Loss: Net loss of $10.7 million in Q1 2025, compared to $6.6 million in Q1 2024.
Cash Position: As of March 31, 2025, ProFound had cash of $46.4 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: ProFound Medical Corporation has not announced any share buyback program or dividend program during the Q1 2025 earnings call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What feedback have you received after the CAPTAIN data release?
A:The feedback was better than anticipated, with many teaching hospitals eager to see the data to drive adoption and integrate it into guidelines.
Q:When will you start presenting the CAPTAIN data to commercial insurers?
A:Conversations with insurers have begun, and there is a positive outlook on getting policies established.
Q:Can you provide context on the booth activity at AUA?
A:The booth activity was fantastic, with high interest from physicians and positive feedback on the volume reduction module.
Q:What is the current guidance for the year?
A:Q1 is in line with the previously mentioned growth range of 70% to 75%, but the transition to a capital model will lead to back-end loaded operations.
Q:What is the status of your sales force and resources?
A:The sales force is fully ramped, with a dedicated team for health economics and market access, and a nurse education team in place.
Q:What engagement have you seen with Medicare and Medicaid patients?
A:Initial impact from reimbursement was limited, but there is growing engagement and billing activity from hospitals.
Q:What are your marketing plans?
A:Marketing efforts are ramping up, including digital and social media campaigns, with plans to utilize satisfied patients as spokespeople.
Q:Can you provide more detail on the capital revenue for the quarter?
A:Most capital revenue came from new sites, with two new installations and one conversion.
Q:What is the timing for TULSA+ availability?
A:Expected by the end of Q3, with announcements of deals anticipated.
Q:What is the structure of the TULSA+ agreement with Siemens?
A:The focus is on driving TULSA procedures, with flexibility in how the MR component is handled.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact number of deals expected to close in the near term, stating that they cannot predict exact timelines for revenue generation from the pipeline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI volume
BPH
Head
Magnetom FreeMax
Medicare insurance
Medicare rate
PRO
ProFound
Tesla
arm
assumption Medicare
blood loss
cash flow
catalyst
cost ownership
day procedure
demand adoption
equipment manufacturer
event need
feasibility
fulguration
grade event
insurance Medicare
key
outcome
patient hospital
place service
post treatment
price
procedure week
rate insurance
recovery
reduction module
safety design
solution
stay
surgeon
treatment patient
volume reduction
PROF Transcript
Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call presented strong financial performance with a 104% revenue increase YoY and improved gross margins. Despite a net loss, the reduction is notable. The Q&A highlighted a strong sales pipeline and positive reimbursement rates from private payers. While guidance was conservative, the company's bullish outlook and solid pipeline suggest potential growth. The market's response may be positive, especially with the anticipation of guideline recognition and commercial payer coverage. However, challenges in MR system integration and competitive pressures should be monitored. Overall, the sentiment leans towards a positive stock price movement.
Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.
Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Positive8-14
The earnings call highlights strong financial performance with improved gross margins and revenue growth. The CAPTAIN trial data and positive feedback from physicians enhance confidence in TULSA's efficacy. Although there are increased operating expenses and net losses, management's optimistic guidance, strategic partnerships, and successful marketing initiatives signal potential for growth. The Q&A session confirms positive sentiment, with plans for reduced cash burn and strategic expansions. The absence of negative guidance, coupled with favorable reimbursement scenarios, supports a positive outlook for the stock price over the next two weeks.
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Unknown5-9
The earnings call presents a mixed picture: strong revenue growth and promising product development (TULSA AI and CAPTAIN trial) are offset by increased net losses and operating expenses. The Q&A section reveals positive feedback on CAPTAIN data and insurer engagement, but management's vague responses on deal closures and financial guidance introduce uncertainty. The lack of shareholder return initiatives further tempers optimism. Despite potential for future growth, current financial instability and competitive pressures suggest a neutral stock price movement in the short term.
PROF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
